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INTRODUCTION
Gonorrhea is a common sexually transmitted disease that, if untreated, can cause 
reproductive health complications. Gonorrhea treatment has been repeatedly jeopardized by 
antimicrobial resistance. To ensure effective treatment, the Centers for Disease Control and 
Prevention (CDC) periodically updates treatment guidelines based on resistance trends. In 
2010 and following declining cephalosporin susceptibility in several countries, CDC 
updated its treatment recommendation from single-dose cephalosporin (injectable 
ceftriaxone or oral cefixime) to intensified combination therapy of either ceftriaxone (at a 
higher dose than previously recommended) or cefixime, plus a second antimicrobial.1 CDC 
again updated guidelines in 2012 to recommend ceftriaxone-based combination therapy as 
the single recommended therapy.1 We describe recent gonococcal cephalosporin 
susceptibility trends emphasizing changes following publication of these guidelines.
METHODS
We analyzed 2006–2014 data from CDC’s Gonococcal Isolate Surveillance Project (GISP), 
a sentinel system which monitors antimicrobial susceptibility in urethral isolates from 
consecutive men with gonorrhea in US public sexually transmitted disease clinics.2 
Jurisdictions competitively apply to participate. GISP is not designed to be nationally 
representative, but rather to detect emerging changes in susceptibility. Susceptibility is 
determined by agar dilution. Isolates with ceftriaxone minimum inhibitory concentrations 
≥0.125 μg/mL or cefixime minimum inhibitory concentrations ≥0.25 μg/mL were 
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categorized as exhibiting reduced susceptibility. Trends were examined overall (and tested 
for significance [two-sided P <0.05] by the Cochran-Armitage trend test) and stratified by 
region and gender of sex partner. Analyses were conducted using SAS version 9.3 (SAS 
Institute). GISP was determined by the Office of the Associate Director for Science, 
National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, CDC to be a 
surveillance activity rather than human subject research; isolates are collected during clinical 
care and separate consent is not required. Gonorrhea is notifiable; health departments have 
authority to collect and transmit case data to CDC.
RESULTS
During 2006–2014, 51,144 isolates were collected in 34 cities. Most isolates were collected 
in the West (36.6%) or South (32.2%); gay, bisexual or other men who have sex with men 
contributed 28.1% of isolates. The percentage of participants treated with ceftriaxone 250 
mg intramuscularly increased from 8.7% (95% confidence interval [CI] 8.0%–9.5%) in 2006 
to 96.6% (96.1%–97.1%) in 2014 (p<0.001). The percentage of isolates with reduced 
cefixime susceptibility increased from 0.1% (<0.1%–0.2%) in 2006 to 1.4% (1.1%–1.7%) in 
2011, and then declined to 0.4% (0.3%–0.6%) in 2013 (Figure). In 2014, the percentage was 
0.8% (0.5%–1.0%). Among isolates from men who have sex with men, the percentage with 
reduced susceptibility peaked at 4.0% (3.1%–5.0%) and was 1.3% (0.8%–1.9%) in 2014 
(Table). Among men who report sex exclusively with women, the percentage remained low. 
In regards to ceftriaxone, the annual overall percentage of isolates with reduced 
susceptibility fluctuated between 0.1% (<0.1%–0.1%) and 0.4% (0.2%–0.6%) (Figure).
DISCUSSION
The prevalence of reduced cefixime susceptibility declined nearly 70% between 2011 and 
2013, suggesting a halting of a drift towards resistance. Although this improvement in 
susceptibility appears temporally correlated with treatment guideline changes, we cannot 
establish a causal relationship. Observed susceptibility trends mirror those in other countries, 
only some of which changed treatment guidance to ceftriaxone-based dual therapy.3,4 Other 
factors, such as mutation fitness costs or faltering transmission of a clone, might have 
contributed to improved susceptibility. The 2014 data, however, suggest that improvements 
in susceptibility may be short-lived.
Although sampling is systematic, participants and participating sites are not selected at 
random. Thus, prevalence data from participating sites are not expected to be nationally 
representative. However, data from GISP have been found to reflect trends in other U.S. 
settings and populations.5,6 Not all jurisdictions participated continuously during 2006–
2014. GISP data cannot distinguish incident infections from repeated sampling of the same 
infection (although this is expected to be rare).
The increased prevalence of reduced cefixime susceptibility in 2014 highlights the need to 
maintain surveillance, search for new therapeutics, and ensure that gonorrhea is treated 
according to CDC guidelines.
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Percentage of urethral Neisseria gonorrhoeae isolates with reduced cefixime susceptibility 
(minimum inhibitory concentrations ≥0.25 μg/ml) or reduced ceftriaxone susceptibility 
(minimum inhibitory concentrations ≥0.125 μg/ml) by year, Gonococcal Isolate Surveillance 
Project, 2006–2014.
NOTE: cefixime susceptibility not tested in 2007 and 2008
MIC=minimum inhibitory concentration
Trend of percentage with elevated cefixime MICs from 2006–2011 (p<0.001); 2011–2013 
(p<0.001), 2013–2014 (p=0.02 by chi-square)
Trend of percentage with elevated ceftriaxone MICs from 2006–2011 (p<0.001); 2011–2013 
(p<0.001), 2013–2014 (p=0.13 by chi-square)
Kirkcaldy et al. Page 4



































































































































































































































































































































































































































































































































































































































































































































































































































































































JAMA. Author manuscript; available in PMC 2016 November 03.
